General Biotechnology

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Cell therapy: European legal and regulatory implications
Go to paperABSTRACT: This paper reviews some of the legal and regulatory considerations that may a…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioterrorism and bioethics: Challenges for industry, government and society
Go to paperABSTRACT: The emerging threat of bioterrorism raises important chall…

This is a guest post by Gerry Langeler, Managing Director with OVP Venture Partners. Do you have a response to Gerry’s

I have been struggling to understand the utility of Google Glass in most of the presented use cases. The Google Glass

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ATMP in practice: Towards a new industry landscape in tissue engineering
Go to paperABSTRACT: Regulatory divergences and market fragmentation across member…

The April 1 2014 issue of the Journal of Commercial Biotechnology has just been published, and features the following papers:

If you walk into most private biotech company boardrooms today, it is likely that you will hear a discussion about whether to go public. Companies at every stage of development are either getting ready to file for an initial public offering or thinking…

Industrial biotechnology is the commercial application of biotechnology using cells or components of cells, like enzymes, for industrial production processes including consumer goods, bioenergy and biomaterials. In the last years this area has gone thr…

Ihave had the pleasure of participating in national forums on biotechnology development in diverse countries. A common theme I see is that emerging economies wish to develop ‘a biotechnology industry like the United States.’ I generally temper these ambitions by explaining that the United States does not have a biotechnology industry per se, but rather a handful of states have very strong biotechnology concentrations and many other states are still trying to build their domestic biotechnology industries. So the lesson for many emerging economies is to set ambitions at the US-state level rather than the US-national level. Furthermore, I also caution against aiming for drug development. Drug development is extremely expensive and risky—focusing on domestic agricultural or industrial biotechnology opportunities may be a better option.

In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and d…